HBV-associated end-stage liver disease
Conditions
Interventions
Tenofovir amibufenamide antiviral therapy group:No
Entecavir, tenofovir disoproxil fumarate, Entecavir+ tenofovir disoproxil fumarate antiviral therapy group:No
Sponsors
The Third Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: ? The age ranges from 18 to 60; ? It meets the clinical diagnostic criteria of decompensated cirrhosis and chronic acute liver failure in the Guidelines for Diagnosis and Treatment of Liver Failure (2018 Edition); ?HBsAg positive over 6 months; ? Control group: ETV, TDF, ETV+TDF antiviral therapy; ? Observation group: TMF application =2 weeks at the time of enrollment; ? Good compliance and voluntary signing of informed consent
Exclusion criteria
Exclusion criteria: ? < 18 years old or = 60 years old; ? TAF was used to treat HBV; ? Complicated with HCV infection, alcoholic liver disease, autoimmune liver disease, metabolism-related fatty liver disease and other liver diseases; ? Syphilis, HIV and other malignant tumors; ?Other severe acute and chronic extrahepatic diseases that affect prognosis, such as COPD and chronic respiratory failure; Uremic stage of chronic kidney disease (dialysis treatment); Coronary heart disease with left heart failure; ? The patient refused to sign the informed consent to participate in this study; ? None of the above are consistent, but the patient cannot sign the informed consent temporarily due to coma and other reasons, and there is no legal agent to sign instead. Depending on the condition, the patient may not wake up to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBV DNA;AFP;PIVKA-II;ALB;TBIL;DBIL;CREA;PT;PTA;INR;WBC;RBC;PLT; | — |
Countries
China
Contacts
Public ContactZhao caiyan
The Third Hospital of Hebei Medical University
Outcome results
None listed